Ductal Carcinoma in Situ of the Breast
Dana-Farber Cancer Institute · Harvard University · +2 more institutions
Abstract
Ductal carcinoma in situ of the breast (also called intraductal carcinoma), a clonal proliferation of malignant-appearing cells within the mammary duct lumens without evidence of invasion beyond the epithelial basement membrane, is the precursor lesion of invasive breast cancer. In the past 20 years, concomitant with the wide use of screening mammography, its detected incidence has risen dramatically. Data from large cohort studies and randomized trials have emerged to guide treatment. This review summarizes progress in the understanding, pathogenesis, and treatment of ductal carcinoma in situ.
Citation impact
- FWCI
- 32.58
- Percentile
- 100%
- References
- 105
Authors
5- HJHarold J. BursteinCorresponding
Dana-Farber Cancer Institute, Harvard University, Brigham and Women's Hospital, Dana-Farber Brigham Cancer Center
- KPKornélia Polyák
Dana-Farber Cancer Institute, Dana-Farber Brigham Cancer Center, Harvard University, Brigham and Women's Hospital
- JSJulia S. Wong
Dana-Farber Cancer Institute, Harvard University, Dana-Farber Brigham Cancer Center, Brigham and Women's Hospital
- SCSusan C. Lester
Brigham and Women's Hospital, Harvard University
- CMCarolyn M. Kaelin
Dana-Farber Cancer Institute, Dana-Farber Brigham Cancer Center, Brigham and Women's Hospital, Harvard University
Topics & keywords
- Medicine
- Ductal carcinoma
- Carcinoma in situ
- Breast cancer
- Concomitant
- Basement membrane
- Carcinoma
- Oncology
- Good health and well-being